Notable companies
The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), AstraZeneca PLC (NASDAQ:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Exact Sciences Corp (NASDAQ:EXAS), Sarepta Therapeutics (NASDAQ:SRPT), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT).
Industry description
The investment seeks capital appreciation.
Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.
Market Cap
The average market capitalization across the Franklin Genomic Advancements ETF ETF is 34.19B. The market cap for tickers in the group ranges from 151.48M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is FDMT at 151.48M.
High and low price notable news
The average weekly price growth across all stocks in the Franklin Genomic Advancements ETF ETF was 15%. For the same ETF, the average monthly price growth was 42%, and the average quarterly price growth was 78%. GRAL experienced the highest price growth at 33%, while SRPT experienced the biggest fall at -23%.
Volume
The average weekly volume growth across all stocks in the Franklin Genomic Advancements ETF ETF was -19%. For the same stocks of the ETF, the average monthly volume growth was -23% and the average quarterly volume growth was 48%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 62
P/E Growth Rating: 74
Price Growth Rating: 57
SMR Rating: 79
Profit Risk Rating: 78
Seasonality Score: 18 (-100 ... +100)